IPA / CJC / IGF Blend
This advanced stack layers Ipamorelin (ghrelin), CJC-1295 (GHRH), and IGF-1 LR3 (an extended-half-life IGF-1 analogue). The first two engage both arms of pituitary GH release; IGF-1 LR3 supplies the downstream effector directly.1
IPA / CJC / IGF Blend at a glance
This advanced stack layers Ipamorelin (ghrelin), CJC-1295 (GHRH), and IGF-1 LR3 (an extended-half-life IGF-1 analogue). The first two engage both arms of pituitary GH release; IGF-1 LR3 supplies the downstream effector directly.1
IGF-1 LR3 has a substituted Arg-3 and an N-terminal 13-amino-acid extension giving roughly 80–100× longer half-life than native IGF-1 and reduced binding to IGFBP-3.2 Direct IGF-1 is added when a clinician wants both the pituitary pulse and reliable systemic IGF exposure.
Ipamorelin + CJC-1295 amplify endogenous pulse; IGF-1 LR3 delivers direct IGF-1 exposure at the tissue.1
Reserved for clients whose IGF-1 fails to rise adequately on GHRH/GHRP alone, or whose recovery demands warrant the direct IGF layer.
What the research actually shows
IPA / CJC / IGF Blend has been studied across multiple modalities. The summaries below cite peer-reviewed sources; individual response varies and is not guaranteed.
Three arms of the GH axis engaged simultaneously.
IGF-1 effects on muscle protein synthesis layer onto pituitary pulse.3
Lean mass and adiposity shifts more pronounced than GHRH/GHRP alone.
Direct IGF-1 supports tendon and connective tissue alongside pituitary effects.4
Skin and hair benefits from sustained IGF-1 exposure.
Pharmacy adjusts ratios based on labs and goals.
Your consultation is complimentary. Our medical team reviews your goals, current treatments, and history before recommending anything.
How a IPA / CJC / IGF Blend protocol typically runs at Luxbae
Dosing, cadence, and delivery method are tailored to you. The outline below describes the most common variant; your provider personalizes based on labs, current treatments, and goals.
Baseline IGF-1, fasting insulin, A1C, comprehensive panel.
Nightly injection at protocol-specific dose; titration phase.
IGF-1 rechecked at 4 and 8 weeks; insulin sensitivity watched closely.
Protocols typically run 8–12 weeks with washouts to preserve receptor function.
Frequently sequenced alongside
- CJC / Ipamorelin Blend without IGF for milder protocols.
- Standalone IGF-1 LR3 if only direct IGF is wanted.
- IGF-LR3 / MOTS-c Blend for performance focus.
- Tesa / Ipa / MOTS-c for visceral fat emphasis.
- Morpheus8 for collagen amplification.
Who it’s for — and who should avoid it
IPA / CJC / IGF Blend eligibility is confirmed during your medical consultation; your full medical history must be disclosed.
- Adults with documented low IGF-1.
- Performance and recovery goals.
- Patients who haven’t responded adequately to GHRH/GHRP alone.
- No malignancy history.
- Pregnancy or breastfeeding.
- Children and adolescents.
- Acute infection or autoimmune flare.
- Known peptide hypersensitivity.
- Active or recent malignancy.
- Untreated severe sleep apnea.
- Active proliferative retinopathy.
- Insulin resistance or T2D without close monitoring.
- Active diabetic retinopathy.
Possible side effects
Injection-site reactions, hypoglycemia risk (especially with IGF-1 LR3), water retention, occasional joint stiffness.
FDA & regulatory note
None of the three components is FDA-approved as a compounded blend. Prescribed under direct medical supervision.
Dr. Ernst von Schwarz, MD, PhD
Professor Dr. Ernst von Schwarz — triple board-certified clinical and academic cardiologist, clinical professor of medicine at UCLA, and a three-decade pioneer in stem cell and regenerative medicine research — personally directs Luxbae’s peptide program. He has authored more than 150 peer-reviewed scientific papers and lectures internationally on cardiovascular and regenerative medicine. Every IPA / CJC / IGF Blend protocol at Luxbae is prescribed and monitored under his direction.
Meet Dr. von SchwarzIPA / CJC / IGF Blend FAQ
Why three instead of two?
Hypoglycemia risk?
Is this safe with diabetes?
Cycle length?
Will my body adapt?
Best timing?
Clinical References
Reviewed by Dr. Ernst von Schwarz and the Luxbae medical team. Statements on this page are educational and supported by the following peer-reviewed sources. Individual results vary.
- Sigalos JT, Pastuszak AW. Safety and Efficacy of GH Secretagogues. Sex Med Rev. 2018;6(1):45-53. View
- Tomas FM, Knowles SE, Owens PC, et al. Insulin-like growth factor-I and more potent variants restore growth of diabetic rats. Biochem J. 1991;276(Pt 2):547-554. View
- Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008;154(3):557-568. View
- Provenzano PP, Alejandro-Osorio AL, Valhmu WB, et al. Intrinsic fibroblast-mediated remodeling of damaged collagenous matrices in vivo. Matrix Biol. 2005. View
Start your IPA / CJC / IGF Blend protocol at Luxbae West Hollywood
Your consultation is complimentary. We’ll walk you through how IPA / CJC / IGF Blend fits your goals, what labs (if any) we’d run, and how it would sequence with the rest of your aesthetic plan.